In therapeutic tumor vaccination settings, vaccination with the OVA SLP fused or not to Xcl1-Fc fusion proteins enhanced CD8+ T cell responses and delayed B16.OVA tumor growth. The gene discussed is CD8A; the disease is neoplasm.